OBJECTIVES: Minimal residual disease (MRD) status in multiple myeloma (MM) is an important prognostic biomarker. Personalized blood-based targeted mass spectrometry detecting M-proteins (MS-MRD) was shown to provide a sensitive and minimally invasive alternative to MRD-assessment in bone marrow. However, MS-MRD still comprises of manual steps that hamper upscaling of MS-MRD testing. Here, we introduce a proof-of-concept for a novel workflow using data independent acquisition-parallel accumulation and serial fragmentation (dia-PASEF) and automated data processing. METHODS: Using automated data processing of dia-PASEF measurements, we developed a workflow that identified unique targets from MM patient sera and personalized protein sequence databases. We generated patient-specific libraries linked to dia-PASEF methods and subsequently quantitated and reported M-protein concentrations in MM patient follow-up samples. Assay performance of parallel reaction monitoring (prm)-PASEF and dia-PASEF workflows were compared and we tested mixing patient intake sera for multiplexed target selection. RESULTS: No significant differences were observed in lowest detectable concentration, linearity, and slope coefficient when comparing prm-PASEF and dia-PASEF measurements of serial dilutions of patient sera. To improve assay development times, we tested multiplexing patient intake sera for target selection which resulted in the selection of identical clonotypic peptides for both simplex and multiplex dia-PASEF. Furthermore, assay development times improved up to 25× when measuring multiplexed samples for peptide selection compared to simplex. CONCLUSIONS: Dia-PASEF technology combined with automated data processing and multiplexed target selection facilitated the development of a faster MS-MRD workflow which benefits upscaling and is an important step towards the clinical implementation of MS-MRD.

Biochemistry Laboratory Hospital of Nantes Nantes France

Bruker Daltonics GmbH Bremen Germany

Bruker Ltd Milton CA USA

Bruker S R O Brno City Czech Republic

Department of Neurology Erasmus MC University Medical Center Rotterdam The Netherlands

Laboratory of Medical Immunology Department of Laboratory Medicine Radboud University Medical Center Nijmegen The Netherlands

Sebia Lisses France

Translational Metabolic Laboratory Department of Human Genetics Radboud University Medical Center Nijmegen The Netherlands

See more in PubMed

van de Donk, N, Pawlyn, C, Yong, KL. Multiple myeloma. Lancet 2021;397:410–27. https://doi.org/10.1016/s0140-6736(21)00135-5 . DOI

Dimopoulos, M, Kyle, R, Fermand, JP, Rajkumar, SV, San Miguel, J, Chanan-Khan, A, et al.. Consensus recommendations for standard investigative workup: report of the international myeloma workshop consensus panel 3. Blood 2011;117:4701–5. https://doi.org/10.1182/blood-2010-10-299529 . DOI

Mills, JR, Kohlhagen, MC, Dasari, S, Vanderboom, PM, Kyle, RA, Katzmann, JA, et al.. Comprehensive assessment of M-proteins using nanobody enrichment coupled to MALDI-TOF mass spectrometry. Clin Chem 2016;62:1334–44. https://doi.org/10.1373/clinchem.2015.253740 . DOI

Puig, N, Contreras, MT, Agullo, C, Martinez-Lopez, J, Oriol, A, Blanchard, MJ, et al.. Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma. Blood Adv 2022;6:3234–9. https://doi.org/10.1182/bloodadvances.2021006762 . DOI

Kumar, S, Paiva, B, Anderson, KC, Durie, B, Landgren, O, Moreau, P, et al.. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:328–46. https://doi.org/10.1016/s1470-2045(16)30206-6 . DOI

Bertamini, L, Oliva, S, Rota-Scalabrini, D, Paris, L, More, S, Corradini, P, et al.. High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma. J Clin Oncol 2022;40:3120–31. https://doi.org/10.1200/jco.21.01393 . DOI

Derman, BA, Fonseca, R. Measurable residual disease and decision-making in multiple myeloma. Hematol Oncol Clin N Am 2024;38:477–95. https://doi.org/10.1016/j.hoc.2023.12.009 . DOI

Garces, JJ, Cedena, MT, Puig, N, Burgos, L, Perez, JJ, Cordon, L, et al.. Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma. J Clin Oncol 2022;40:3151–61. https://doi.org/10.1200/jco.21.01365 . DOI

Jelinek, T, Bezdekova, R, Zihala, D, Sevcikova, T, Anilkumar Sithara, A, Pospisilova, L, et al.. More than 2 % of circulating tumor plasma cells defines plasma cell leukemia-like multiple myeloma. J Clin Oncol 2023;41:1383–92. https://doi.org/10.1200/jco.22.01226 . DOI

Mack, EKM, Hartmann, S, Ross, P, Wollmer, E, Mann, C, Neubauer, A, et al.. Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cells. Ann Hematol 2022;101:811–24. https://doi.org/10.1007/s00277-022-04771-5 . DOI

Barnidge, DR, Tschumper, RC, Theis, JD, Snyder, MR, Jelinek, DF, Katzmann, JA, et al.. Monitoring M-proteins in patients with multiple myeloma using heavy-chain variable region clonotypic peptides and LC-MS/MS. J Proteome Res 2014;13:1905–10. https://doi.org/10.1021/pr5000544 . DOI

Bergen, HR3rd, Dasari, S, Dispenzieri, A, Mills, JR, Ramirez-Alvarado, M, Tschumper, RC, et al.. Clonotypic light chain peptides identified for monitoring minimal residual disease in multiple myeloma without bone marrow aspiration. Clin Chem 2016;62:243–51. https://doi.org/10.1373/clinchem.2015.242651 . DOI

Liyasova, M, McDonald, Z, Taylor, P, Gorospe, K, Xu, X, Yao, C, et al.. A personalized mass spectrometry-based assay to monitor M-protein in patients with multiple myeloma (EasyM). Clin Cancer Res 2021;27:5028–37. https://doi.org/10.1158/1078-0432.ccr-21-0649 . DOI

Martins, CO, Huet, S, Yi, SS, Ritorto, MS, Landgren, O, Dogan, A, et al.. Mass spectrometry-based method targeting Ig variable regions for assessment of minimal residual disease in multiple myeloma. J Mol Diagn 2020;22:901–11. https://doi.org/10.1016/j.jmoldx.2020.04.002 . DOI

McDonald, Z, Taylor, P, Liyasova, M, Liu, Q, Ma, B. Mass spectrometry provides a highly sensitive noninvasive means of sequencing and tracking M-protein in the blood of multiple nyeloma patients. J Proteome Res 2021;20:4176–85. https://doi.org/10.1021/acs.jproteome.0c01022 . DOI

Noori, S, Wijnands, C, Langerhorst, P, Bonifay, V, Stingl, C, Touzeau, C, et al.. Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry. Blood Cancer J 2023;13:30. https://doi.org/10.1038/s41408-023-00803-z . DOI

Remily-Wood, ER, Benson, K, Baz, RC, Chen, YA, Hussein, M, Hartley-Brown, MA, et al.. Quantification of peptides from immunoglobulin constant and variable regions by LC-MRM MS for assessment of multiple myeloma patients. Proteonomics Clin Appl 2014;8:783–95. https://doi.org/10.1002/prca.201300077 . DOI

Wijnands, C, Langerhorst, P, Noori, S, Keizer-Garritsen, J, Wessels, H, Gloerich, J, et al.. M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator. Clin Chem Lab Med 2024;62:540–50. https://doi.org/10.1515/cclm-2023-0781 . DOI

Zajec, M, Jacobs, JFM, Groenen, P, de Kat Angelino, CM, Stingl, C, Luider, TM, et al.. Development of a targeted mass-spectrometry serum assay to quantify M-protein in the presence of therapeutic monoclonal antibodies. J Proteome Res 2018;17:1326–33. https://doi.org/10.1021/acs.jproteome.7b00890 . DOI

Langerhorst, P, Noori, S, Zajec, M, De Rijke, YB, Gloerich, J, van Gool, AJ, et al.. Multiple myeloma minimal residual disease detection: targeted mass spectrometry in blood vs next-generation sequencing in bone marrow. Clin Chem 2021;67:1689–98. https://doi.org/10.1093/clinchem/hvab187 . DOI

Di Noia, JM, Neuberger, MS. Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem 2007;76:1–22. https://doi.org/10.1146/annurev.biochem.76.061705.090740 . DOI

Dudley, DD, Chaudhuri, C, Bassing, CH, Alt, FW. Mechanism and control of V(D)J recombination versus class switch recombination: similarities and differences. Adv Immunol 2005;86:43–112. https://doi.org/10.1016/s0065-2776(04)86002-4 . DOI

Mendes, ML, Dittmar, G. Targeted proteomics on its way to discovery. Proteomics 2022;22:e2100330. https://doi.org/10.1002/pmic.202100330 . DOI

Integraal kankercentrum Nederland. Available from: https://iknl.nl/kankersoorten/hemato-oncologie/nkr-cijfers/mm [Accessed November 2023].

Lesur, A, Bernardin, F, Koncina, E, Letellier, E, Kruppa, G, Schmit, PO, et al.. Quantification of 782 plasma peptides by multiplexed targeted proteomics. J Proteome Res 2023;22:1630–8. https://doi.org/10.1021/acs.jproteome.2c00575 . DOI

Krasny, L, Huang, PH. Data-independent acquisition mass spectrometry (DIA-MS) for proteomic applications in oncology. Mol Omics 2021;17:29–42. https://doi.org/10.1039/d0mo00072h . DOI

Attal, M, Lauwers-Cances, V, Hulin, C, Leleu, X, Caillot, D, Escoffre, M, et al.. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 2017;376:1311–20. https://doi.org/10.1056/nejmoa1611750 . DOI

MacLean, B, Tomazela, DM, Shulman, N, Chambers, M, Finney, GL, Frewen, B, et al.. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 2010;26:966–8. https://doi.org/10.1093/bioinformatics/btq054 . DOI

Xu, T, Park, SK, Venable, JD, Wohlschlegel, JA, Diedrich, JK, Cociorva, D, et al.. ProLuCID: an improved SEQUEST-like algorithm with enhanced sensitivity and specificity. J Proteonomics 2015;129:16–24. https://doi.org/10.1016/j.jprot.2015.07.001 . DOI

Bolotin, DA, Poslavsky, S, Mitrophanov, I, Shugay, M, Mamedov, IZ, Putintseva, EV, et al.. MiXCR: software for comprehensive adaptive immunity profiling. Nat Methods 2015;12:380–1. https://doi.org/10.1038/nmeth.3364 . DOI

Stingl, C, Luider, TM. Applying log-normal peak fitting to parallel reaction monitoring data analysis. J Proteome Res 2021;20:4186–92. https://doi.org/10.1021/acs.jproteome.1c00371 . DOI

Demichev, V, Messner, CB, Vernardis, SI, Lilley, KS, Ralser, M. DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput. Nat Methods 2020;17:41–4. https://doi.org/10.1038/s41592-019-0638-x . DOI

Food and Drug Administration . Bioanalytical method validation guidance for industry. Available from: https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf [Accessed June 2023].

Perez-Riverol, Y, Bai, J, Bandla, C, Garcia-Seisdedos, D, Hewapathirana, S, Kamatchinathan, S, et al.. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res 2022;50:543–52. https://doi.org/10.1093/nar/gkab1038 . DOI

Wijnands, C, Noori, S, Donk, N, VanDuijn, MM, Jacobs, JFM. Advances in minimal residual disease monitoring in multiple myeloma. Crit Rev Clin Lab Sci 2023;60:518–34. https://doi.org/10.1080/10408363.2023.2209652 . DOI

Li, C, Chu, S, Tan, S, Yin, X, Jiang, Y, Dai, X, et al.. Towards higher sensitivity of mass spectrometry: a perspective from the mass analyzers. Front Chem 2021;9:813359. https://doi.org/10.3389/fchem.2021.813359 . DOI

Sawicki, R, Korona-Glowniak, I, Boguszewska, A, Stec, A, Polz-Dacewicz, M. Sample pooling as a strategy for community monitoring for SARS-CoV-2. Sci Rep 2021;11:3122. https://doi.org/10.1038/s41598-021-82765-5 . DOI